References
- Through website: https://en.wikipedia.org/wiki/Sofosbuvir (accessed December 2, 2015, 11:05 AM).
- Through website: http://www.hepatitisc.uw.edu/page/treatment/drugs/ledipasvir-sofosbuvir (accessed December 2, 2015, 11 AM).
- Berden, F. A.; Drenth, J. P. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. Netherlands J. Med. 2014, 72, 388–400.
- Cholongitas, E.; Papatheodoridis, G. V. Sofosbuvir: A novel oral agent for chronic hepatitis C. Ann. Gastroenterol. 2014, 27, 331–337.
- Cha, A.; Budovich, A. Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection. Pharm. Therap. 2014, 39, 345–352.
- Through website: https://www.gilead.com/~/media/.../harvoni_pi.pdf (accessed December 2, 2015, 11:30 AM).
- Averhoff, F. M.; Glass, N.; Holtzman, D. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clin. Infect. Dis. 2012, 55, S10–S15. doi:10.1093/cid/cis361
- Through website: http://www.sphinx-hcv.eu/About-Hepatitis-C/hepatitis-c-in-egypt.html (accessed December 2, 2015, 11:45 AM).
- Gilead Sciences, Inc. SOVALDI Product Monograph. Foster City, CA. December 6, 2013.
- Gilead Sciences Canada, Inc. SOVALDI Product Monograph. Mississauga, ON. December 12, 2013.
- Link, J. O.; Taylor, J. G.; Xu, L.; Mitchell, M.; Guo, H.; Liu, H.; Katp, D.; Kirschberg, T.; Sun, J.; Squires, N.; Parrish, J.; Keller, T.; Yang, Z.-Y.; Yang, C.; Matles, M.; Wang, Y.; Wang, K.; Cheng, G.; Tian, Y.; Mogalian, E.; Mondou, E.; Compropst, M.; Perry, J.; Desai, M. C. Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 2014, 57 (5), 2033–2046.
- Kueltzo, L. A.; Wang, W.; Randolph, T. W.; John, F. C. Effects of Solution Conditions, Processing Parameters, and Container Materials on Aggregation of a Monoclonal Antibody during Freeze-Thawing. J. Pharm. Sci. 2008, 97 (5), 1801–1812.
- Webb, S. D.; Webb, J. N.; Sesin, D. F.; Hughes, T. G. Freezing biopharmaceuticals using common techniques and the magnitude of bulk scale freeze concentration. BioPharm Int. 2002, 15, 22–34.
- Shi, X.; Zhu, D.; Lou, J.; Zhu, B.; Hu, A. R.; Gan, D. Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2015, 1002, 353–357. doi:10.1016/j.jchromb.2015.08.038
- Rezk, M. R., Basalious, E. B., Karim, I. A. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. J. Pharm. Biomed. Anal. 2015. doi:10.1016/j.jpba.2015.05.006
- The United States Pharmacopeia”, National Formulary 35, United States Pharmacopeia Convention Inc., 30th Ed., 2012.
- Abdelwahab, N. S. Spectrophotometric methods for simultaneous determination of Carvedilol and Hydrochlorothiazide in combined dosage form. Arab. J. Chem. 2011. doi:10.1016/j.arabjc.2011.05.002
- Abdelwahab, N. S., Abdelaleem, E. A. Stability Indicating RP-HPLC Method for Simultaneous Determination of Guaifenesin and Pseudoephedrine Hydrochloride in Presence of Syrup Excepients. Arab. J. Chem. 2013. doi:10.1016/j.arabjc.2013.11.019